26.03.2015
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 Confirms Earnings Increase of 28.6 Percent per Share 2014
DGAP-News: Vita 34 AG / Key word(s): Final Results
Vita 34 Confirms Earnings Increase of 28.6 Percent per Share 2014
26.03.2015 / 07:33
---------------------------------------------------------------------
Vita 34 Confirms Earnings Increase of 28.6 Percent per Share 2014
Leipzig March 26, 2015 - Vita 34 AG (WKN A0BL84) continued its 2014 growth
trend and published its complete 2014 annual report today. Thanks to the
ongoing positive profit situation, the Management Board and Supervisory
Board have proposed for the first time to the Annual General Meeting the
payment of a dividend. A dividend in the amount of EUR 0.15 per share is to
be paid for fiscal year 2014.
The period result improved by 25.6 percent in fiscal year 2014 compared to
the year before. The earnings per share increased by 28.6 percent to EUR
0.36 (2013: EUR 0.28). This positive development is reflected in the key
group figures:
- Total operating revenue EUR 15.2 million (2013: EUR 14.8 million) +2.7%
- Sales revenue EUR 13.8 million (2013: EUR 13.6 million) +1.7%
- EBITDA EUR 2.8 million (2013: EUR 2.7 million) +4.4%
- EBIT EUR 1.7 million (2013: EUR 1.5 million) +15.0%
- Period result EUR 1.0 million (2013: EUR 0.8 million) +25.6%
The profitability can be attributed, in particular, to an optimized cost
structure. In addition, income from a positive court decision in favor of
Vita 34 was posted.
Within the scope of the growth strategy, Vita 34 has extended its presence
in Europe and advanced its activities in South East Asia In the reporting
period. Consequently the penetration and opening of new markets will
continue in the new fiscal year 2015.
Vita 34 intends to expand the value chain with new products for
pharmaceutical production and, thus, persistently strengthen its market
position as a specialist in the cryo-preservation of biological materials.
In fiscal year 2014 the VitaPlusCord product was established in the
German-speaking region, as well as via local sales partners in the European
market. Stem cell deposits from umbilical cord tissue from several
countries are already being stored in Leipzig.
Vita 34 has further identified additional possibilities for the isolation
of stem cells from other tissues in the course of its research and
development activities. In particular, the research project involving the
cryo-preservation of stem cells from fatty tissue started in fiscal year
2014 will be consistently pursued in the current fiscal year.
In light of the strong market position, with a solid equity ratio of some
60 percent and cash of EUR 3.7 million, Dr. André Gerth is looking forward
to future corporate development with confidence: "As the undisputed market
leader in the German-speaking countries, we are well equipped for the
future. We will use our increased profitability in order to achieve
significantly more aggressive revenue and profit growth within the context
of a Buy and Build strategy in the medium term. The three core of our
growth strategy - market penetration and the opening of new markets, the
development of the product ranges, as well as the expansion of research
activities - form the foundation for this," says Dr. André Gerth.
Due to the ongoing tense economic situation in Europe and the necessary
expenditures for implementing its corporate strategy, Vita 34 expects total
operating revenues and an operating result (EBITDA) at the 2014 level for
the current fiscal year. Vita 34 expects that EBIT, EBITDA margin and the
number of newly stored stem cell deposits will also be at last year's
levels. In addition, an equity ratio of some 60 percent has been set as a
goal.
The complete Annual Report 2014 is available for download now on the
website at www.vita34group.com in the "Investor Relations" section.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and cord tissue. The basis
for its successful work is an outstanding position in the technological
segment of cryo-preservation. Here, cells and tissue are preserved alive at
some -190ºC for long periods of time, and can be used if needed in the
context of medical treatment. More than 123,000 families are already taking
advantage of this offering and have provided for their children with a stem
cell deposit at Vita 34.
---------------------------------------------------------------------
26.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
337683 26.03.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V